T-cell therapy (Tevogen Bio)

N/A

Report date: 2025/01/26 16:34:18

Base Information

Drug NameT-cell therapy (Tevogen Bio)
Drug Alias Nameallogeneic CD8+ T-lymphocyte therapy (Tevogen Bio)allogeneic TCR T-cell therapy (Tevogen Bio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTevogen Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTevogen Bio Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A